The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method of inhibiting restenosis comprising administering to a patient in need thereof a composition comprising an ADP receptor antagonist and a thromboxane A_2 receptor antagonist.

2. The method of Claim 1, wherein the ADP receptor antagonist is selected from the group consisting of ticlopidine and clopidogrel.

3. The method of Claim 1, wherein the ADP receptor antagonist comprises clopidogrel.

4. The method of Claim 1, wherein the thromboxane A_2 receptor antagonist comprises ridogrel.

5. The method of Claim 1, wherein the composition is locally administered to a vascular site.

6. The method of Claim 5, wherein the composition is administered perioperatively during a vascular procedure.

7. The method of Claim 1, wherein the composition is administered perioperatively during a vascular procedure.

8. The method of Claim 1, wherein the ADP receptor antagonist and the thromboxane A_2 receptor antagonist are each in solution in a physiologic liquid carrier at a concentration of no greater than 100,000 nanomolar.

9. The method of Claim 1, wherein the ADP receptor antagonist and the thromboxane A_2 receptor antagonist are each in solution in a physiologic liquid carrier at a concentration of no greater than 10,000 nanomolar.

10. A composition for the inhibition of restenosis comprising an ADP receptor antagonist and a thromboxane A_2 receptor antagonist.

11. The composition of Claim 10, wherein the ADP receptor antagonist is selected from the group consisting of ticlopidine and clopidogrel.

12. The composition of Claim 10, wherein the ADP receptor antagonist comprises clopidogrel.

13. The composition of Claim 10, wherein the thromboxane A_2 receptor antagonist comprises ridogrel.

14. The composition of Claim 10, wherein the ADP receptor antagonist and the thromboxane A_2 receptor antagonist are each in solution in a physiologic liquid carrier at a concentration of no greater than 100,000 nanomolar.

15. The composition of Claim 10, wherein the ADP receptor antagonist and the thromboxane A_2 receptor antagonist are each in solution in a physiologic liquid carrier at a concentration of no greater than 10,000 nanomolar.

16. A method of inhibiting platelet aggregation comprising administering to a patient in need thereof a composition comprising an ADP receptor antagonist and a thromboxane A_2 receptor antagonist.

17. The method of Claim 16, wherein the ADP receptor antagonist is selected from the group consisting of ticlopidine and clopidogrel.

18. The method of Claim 16, wherein the ADP receptor antagonist comprises clopidogrel.

19. The method of Claim 16, wherein the thromboxane A_2 receptor antagonist comprises ridogrel.

20. The method of Claim 16, wherein the composition is locally administered to a vascular site.

21. The method of Claim 20, wherein the composition is administered perioperatively during a vascular procedure.

22. The method of Claim 16, wherein the composition is administered perioperatively during a vascular procedure.

23. The method of Claim 16, wherein the ADP receptor antagonist and the thromboxane A_2 receptor antagonist are each in solution in a physiologic liquid carrier at a concentration of no greater than 100,000 nanomolar.

24. The method of Claim 16, wherein the ADP receptor antagonist and the thromboxane A_2 receptor antagonist are each in solution in a physiologic liquid carrier at a concentration of no greater than 10,000 nanomolar.

25. A cardiovascular therapeutic composition comprising an ADP receptor antagonist and a thromboxane A_2 receptor antagonist.

26. A pharmaceutical combination comprising an ADP receptor blocking antiplatelet drug and a thromboxane A_2 receptor antagonist.

27. The composition of Claim 26, wherein the ADP receptor blocking antiplatelet drug comprises clopidogrel.

28. A method for preventing or inhibiting platelet aggregation in a mammalian species, which comprises administering to a patient in need of treatment a therapeutically effective amount of a pharmaceutical combination as defined in Claim 26.